Oxford Immunotec Global Plc, a U.K. maker of a test for latent tuberculosis, raised $64.3 million in a U.S. initial public offering today, adding fuel to a rebound in listings this year among European biotechnology companies.
Anglo American Plc’s South African unit reached a cash settlement with 23 miners who contracted lung diseases when working at its operations, the first such accord in the nation, lawyers led by Leigh Day & Co. said.
Gilead Sciences Inc ., the world’s biggest maker of AIDS drugs, said it is stopping a late-stage study of an experimental lung-disease therapy because it didn’t help patients with the condition, idiopathic pulmonary fibrosis.
Lawyers for more than 25,000 miners and the dependents of deceased workers who contracted silicosis and tuberculosis while working on South African gold mines filed an application to combine three pending cases against producers.
AngloGold Ashanti Ltd. and Gold Fields Ltd. are among South African producers threatened with costly court battles as rights groups enlist thousands of former miners with work-related lung disease for a class-action suit.
GlaxoSmithKline Plc and Theravance Inc.’s combination treatment for a lung disease that is the No. 3 cause of death in the U.S. showed strong efficacy at both doses the companies sought for approval, regulators said.